Kornimate/medical-research-clean huggingface dataset:
effect of various sealers on healing of teeth with apical periodontitis

Conditions: Apical Periodontitis

Summary: this study will compare the effect of three different sealers on healing of teeth with apical periodontitis after primary root canal treatment.

various sealers with different chemical composition and properties are available but it is yet not clear if one sealer is superior to other in terms of healing of apical periodontitis. three different groups of sealers will be used- a zinc oxide based sealer, an epoxy resin based sealer and a bioactive silicone based sealer. mature mandibular permanent molar with the diagnosis of apical periodontitis (as confirmed clinically \& by periapical radiograph) will be chosen for the study. primary non surgical root canal treatment will be performed. the sealer will be randomly selected just before obturation of root canals. the patient will be allotted to one of the three groups. * group i: zinc oxide eugenol sealer group. the material will be mixed according to manufacturer instructions and applied to canals using a lentulospiral and the obturation will be performed. * group ii: epoxy resin based sealer group. the material will be mixed according to the manufacturer's instructions and obturation will be done. * group iii: bioactive silicone based sealer: the material will be used according to the manufacturer's instruction and obturation will be performed

Eligibility criteria:
inclusion criteria: the inclusion criteria of the study will include: * patient willing to participate in the study. * age \>18 years. * no history of antibiotic use within the past month or requiring antibiotic premedication * no history of prior analgesic use during past 24 hrs. * mature permanent mandibular molar having apical periodontitis requiring primary root canal treatment. * there must be a radiographic evidence of periapical radiolucency (minimum size 2mmx2mm) and a diagnosis of pulpal necrosis, as confirmed by negative response to cold and electrical tests; and absence of bleeding on entering the pulp chamber exclusion criteria: * re-treatment * unwillingness of patients * the presence of a difficult canal anatomy (root canals with an extreme curvature ≥30 deg), internal or external resorption and immature teeth. * accident or complication during treatment (calcified canals ,inability to achieve apical patency in any canals) immuno-compromised, diabetic, pregnant and hypertensive patients. * teeth that are peridontally compromised
cognitive computer training in patients with depression

Conditions: Depression in Remission; Cognitive Computer Training; Returning to Work

Summary: cognitive impairment plays an important role in functional recovery and leads to long-term sickness absence. therefore there is a need of a treatment specifically improving cognitive functions. in this pilot study the investigators aim to evaluate the feasibility of using cognitive computer training in patients with unipolar depression to enhance cognitive performance. further the investigators investigate whether this intervention shortens sick leave.

this study will evaluate cognitive computer training on patients in remission from depression by measuring the compliance and effect, investigating whether patients returned earlier to work and examine patients' physical and psychological health. this is done by comparing an intervention group and a control group. outpatients from psychiatric department odense in denmark will be recruited from december 2015 to july 2017. at enrolment the participants wil be randomized 1:1 to either the intervention group or the control group. after the participants will complete a clinical interview and answer the the short form (36) health survey (sf-36) questionnaire. the participants' cognitive function and depression severity will be measured at baseline and three months follow-up. at nine months follow-up the participants will receive an email with the sf-36 questionnaire and questions about their education and work status, which they were required to answer. the intervention is a cognitive computer program, consisting of different computer games. the intervention will start at enrolment and finish at the three months follow-up. the participants in the intervention group will do trainings session lasting 10-20 minutes three times a week. each participant ends up with a total of 36 training sessions.

Eligibility criteria:
inclusion criteria: * a diagnosis of a moderate to severe unipolar depression according to the international classification of diseases -10 criteria * receiving antidepressant medicine * completed their treatment for depression * not be in any risk of suicide * study or work on reduced hours, be unemployed or on long-term sickness leave at enrolment. exclusion criteria: * neurological disease of the central nervous system * alcohol or substance abuse * pregnancy * receiving disability pension * receiving electroconvulsive therapy within the last 6 weeks.

Keywords: depression cognitive function work
ards caused by covid-19

Conditions: Acute Respiratory Failure With Hypoxia

Summary: patients with the acute respiratory distress syndrome (ards) have markedly varied clinical presentations. main characteristics of mechanically ventilated ards caused by covid-19, and adherence to lung-protective ventilation strategies are not well known.

this is a multicenter, prospective, observational study in consecutive, mechanically ventilated patients with ards caused by covid-19 (as defined by the berlin criteria and confirmed covid-19 infection in a respiratory tract sample), admitted into a network of 27 spanish and andorran intensive care units (icus). clinical features, ventilatory management, and clinical outcomes will be examined

Eligibility criteria:
inclusion criteria: * aged 18 years or older * intubated and mechanically ventilated * confirmed covid-19 infection in a respiratory tract sample * acute onset of ards, as defined by the berlin criteria exclusion criteria: * patients with non-confirmed sars-cov-2 infection according to who guidance * patients with no information on respiratory parameters * non- intubated patients
promoting palliative care for people with heart failure

Conditions: Heart Failure; Palliative Care

Summary: this project will develop and test a novel clinical decision support tool (cds) that encourages timely referral to palliative care for people hospitalized with heart failure. this intervention will incorporate an existing, validated 1-year mortality risk model into a cds to deliver prognostic information and evidence-based decision support at the point of care. thus, this research may lead to improved care-concordant and goal-directed care for people with heart failure.

healthcare providers will encounter the tool during the routine care of their hospitalized patients. providers randomized to the intervention arm will receive training on the use of the tool and complete one post-trial survey. providers randomized to the intervention arm will also have the opportunity to participate in 1 post-trial interview. level 2 providers will participate in one interview.

Eligibility criteria:
inclusion criteria: healthcare providers must meet the following criteria: * are an attending physician, fellow, or resident, advanced practice nurse, or physician associate * has ordering privileges * are members of one of the hospitals' admitting teams (e.g., hospitalist service, cardiology service) * anticipate employment at one of the two study sites for the 15-month trial period. or * palliative care team member * hospital administrator/quality and safety personnel patients of providers enrolled in the study must meet the following criteria for heart failure during hospitalization: * n-terminal pro-b-type natriuretic peptide values of \>500 pg/ml * not pregnant at the time of admission. * received intravenous diuretics within 24 hours of admission. exclusion criteria: -
bristol bladder trial

Conditions: Infiltrating Bladder Urothelial Carcinoma

Summary: 26 patients with invasive primary transitional cell carcinoma of the bladder will receive 4 cycles of combination chemotherapy consisting of cabazitaxel and cisplatin both given intravenously on day 1 of each 3 weekly cycle prior to radical cystectomy, to evaluate the overall response rate and to determine whether this approach warrants further research of a phase ii/iii study.participation in 2 sub studies will also be offered to the participants. 1. contrast magnetic resonance imaging (mri ) scans will be taken at baseline and after cycle 1 and cycle 3. 2. a pilot sub study involving the circulating tumour cell concentration from blood samples taken at baseline, prior to each cycle of chemotherapy and prior to surgery


Eligibility criteria:
inclusion criteria: * age ≥18 years * histologically confirmed primary transitional cell carcinoma (tcc) of the urinary bladder * t2 to t4 disease, n0 m0 determined by computerised tomography (ct) imaging and biopsy or transurethral resection * eastern co-operative oncology group (ecog) performance status 0 or 1 * glomerular filtration rate (gfr) ≥60ml/min. * written, informed consent exclusion criteria * ecog performance status ≥ 2 * lymph node involvement or metastatic disease * prior surgery (except transurethral resection of bladder tumour), radiation, che-motherapy, or other anti-cancer therapy within 4 weeks prior to enrolment * active grade ≥2 peripheral neuropathy * active secondary cancers * history of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs * other concurrent serious illness or medical conditions * inadequate organ function as evidenced by peripheral blood counts at enrolment: * electrocardiogram (ecg) evidence of uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension, history of congestive heart failure, or myocardial infarction within last 6 months. * uncontrolled diabetes mellitus. * active uncontrolled gastro-oesophageal reflux disease (gord). * active infection requiring systemic antibiotic or anti-fungal medication * participation in another clinical trial with any investigational drug within 30 days prior to study enrolment. * concurrent or planned treatment with strong inhibitors of cytochrome p450 3a4/5. a 1-week washout period is necessary for patients who are already on these treatments. * concurrent or planned treatment with strong inducers of cytochrome p450 3a4/5. a 1-week washout period is necessary for patients who are already on these treatments. * contraindications to cisplatin. * patient with reproductive potential not implementing an accepted and effective method of contraception.

Keywords: bladder cancer transitional cell carcinoma urothelial cancer cisplatin cabazitaxel chemotherapy neo adjuvant chemotherapy
human ovarian autotransplantation

Conditions: Ovarian Autotransplantation Using Cryopreserved Ovarian Tissue in Women Treated for Cancer

Summary: chemotherapy can cause permanent damage to a woman's ovaries. women who are cancer survivors may find that they are not able to produce female hormones, and they may not be able to have a child. scientists are trying to find ways to help cancer survivors regain their hormonal function and possibly get pregnant, if they desire. scientists have developed a method where ovarian tissue is removed and frozen before chemotherapy; then it is thawed and put back into the woman's body after she is cancer-free. putting a woman's previously-frozen tissue back into her body is called ovarian autotransplantation. ovarian autotransplantation is a very new technique, and there have only been a small number of women who have had this procedure. so far, only five babies in the world have been born using this technique. the purpose of this study is to learn more about ovarian autotransplantation. scientists hope to find better ways to use this method to help a woman's ovaries start working again after chemotherapy. if the ovaries start working again, it might be possible to have a baby.


Eligibility criteria:
inclusion criteria: * adult women (age between 18 and 40) who stored the ovary before cancer therapy. * adult women who completed cancer therapy and are in remission. * adult women who desire to conceive and are ready to have a baby. exclusion criteria: * age under 18 or over 40 years old * women with a disease at high risk for ovarian metastasis (such as leukemia) * women with contraindication for surgery * women with contraindication for pregnancy * psychological instability to sustain pregnancy (diagnosed by a psychiatrist) * women who are hiv positive

Keywords: women with cancer whose ovarian tissue has been collected and stored in liquid nitrogen before cancer therapy (surgery, chemotherapy, radiotherapy), who are in remission (no recurrence of disease for 5 years), who are in normal organ function and have no contraindication for surgery or pregnancy, and who wish to restore ovarian function using stored ovarian tissue.
genetic basis of hemangiomas

Conditions: Hemangioma, Vascular Anomalies

Summary: the purpose of this study is to determine if there are genes that are common in children with infantile hemangioma. this information will allow physicians to improve care for patients who have been diagnosed with this disease and to provide their parents with more complete information regarding the cause of this disease. this research is being done because many unanswered questions remain regarding children with infantile hemangioma. there are very few medications to treat infants with hemangiomas.

what is involved in the research study? * buccal smear (cheek cells) or small blood sample (4 ml or 1 teaspoon) from child being seen in the dermatology clinic having infantile hemangioma or vascular anomaly * buccal smear (cheek cells) or small blood sample (4 ml or 1 teaspoon) from parents of child if you and your child agree to be in this study, the following will happen: 1. informed consent and permission to use or disclose your/your child's health information for research purposes will be obtained by dr. drolet, the principal investigator, or her research team. you will receive a copy of this consent form. 2. a buccal swab or blood sample will be obtained from you and your child; buccal sampling involves rubbing the inside of your cheek and removing cells to perform a genetic test called "genomewide association (gwa). we expect you and your child to be involved in this study until you and your child have the genetic testing performed.

Eligibility criteria:
study population inclusion criteria: * no limit to age * diagnosis of infantile hemangioma and/or vascular anomaly * unaffected twin sibling * each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent. each patient must also give assent to study participation. study population exclusion criteria: * diagnosis other than infantile hemangioma or vascular anomaly * if the lesion has resolved and cannot be confirmed as a hemangioma by clinical exam * if the biologic parents are unwilling or unable to submit dna samples the child will be excluded from the dna study. therefore, if dna samples cannot be or are not obtained from both biologic parents, the child and family will be excluded from the study.

Keywords: hemangioma vascular anomaly infantile hemangioma
prevention of contrast-induced nephropathy with sodium bicarbonate bolus injection

Conditions: Emergent Coronary Procedure

Summary: this study is to investigate the effect of sodium bicarbonate bolus injection in patients undergoing an emergent coronary procedure for prevention of contrast-induced nephropathy.

this study is to investigate the effect of sodium bicarbonate bolus injection in patients undergoing an emergent coronary procedure for prevention of contrast-induced nephropathy.the end point is development of contrast-induced nephropathy.

Eligibility criteria:
inclusion criteria: * patients undergoing an emergent coronary procedure(within 60 minutes from admission) exclusion criteria: * on dialysis * pregnancy * past use of bicarbonate or n-acetyl-cystein in 48hr * past exposure to contrast media in 48hr * circulatory insufficiency with lactic acidosis.

Keywords: patients undergoing an emergent coronary procedure
worldwide yearly screening for hypospadias

Conditions: Hypospadias

Summary: the purpose of this study is to recruit approximately 20 male participants who have a history of repaired hypospadias to test the feasibility and acceptability of the care planning tool within the worldwide yearly screening for hypospadias (wysh) web application.

several studies show that patients who undergo hypospadias repair report significant functional and psychosexual issues in adolescence or adulthood (in more than 50% of cases). the care planning tool within the worldwide yearly screening for hypospadias (wysh) web application, developed using expert level consensus from a delphi measure including stakeholders (psychologists, urologists, endocrinologists, patients/families), is designed to support the functional and psychosexual health of male youth and adults treated for hypospadias, to support their physical and mental health after repair. this is a pilot study of the wysh intervention to access its feasibility and acceptability.

Eligibility criteria:
inclusion criteria: * males who have a documented history of repaired hypospadias. * age groups targeted, based on recommended standards for user experience data from pilot studies: * 3-5 males, age 5-10 (with parental consent and child assent) * 3-5 males, age 11-15 (with parental consent and child assent) * 3-5 males, age 16-20 (with parent consent, child assent until age 18) * 3-5 males, age 21-65 exclusion criteria: -

Keywords: hypospadias complications quality of life patient-reported outcomes
effects of inulin on satiety and food intake

Conditions: Obesity

Summary: to assess the effect of inulin on appetite profile ratings, food intake and satiety hormones.

based upon a slower digestion and the fermentation in the intestinal tract, food containing soluble dietary fibres, such as inulin, is hypothesized to be more satiating, and to limit energy intake, in humans. does supplementation of inulin (at 2 dosages) versus placebo over 13 consecutive days in normal to overweight men and women, lead to an increase in satiety, a reduction in food intake and stronger postprandial increases in glp-1 and pyy?

Eligibility criteria:
inclusion criteria: * age between 18 and 60 years * bmi between 23 and 28 kg/m2 * dietary unrestraint (tfeq: f1\<9) exclusion criteria: * age under 18 and above 60 years * bmi under 23 and above 28 kg/m2 * dietary restraint (tfeq: f1\>9) * use of medication * pregnant or breastfeeding

Keywords: overweight
dapagliflozin on hypotensive heart failure patients after sacubitril/valsartan therapy

Conditions: Hypotension; Heart Failure

Summary: the dapa-hf trial demonstrated that dapagliflozin was able to reduce the risk of worsening heart failure events and cardiovascular death comparing to placebo in patients with reduced ejection fraction further to standard of care. however, hypotensive patients who generally have higher risks comparing to normotensive patients, were under represented in the dapa-hf. the investigators aimed to evaluate clinical effects of dapagliflozin on hypotensive heart failure patients receiving chronic sacubitril/valsartan treatment.

the dapa-hf trial demonstrated that dapagliflozin was able to reduce the risk of worsening heart failure (hf) events and cardiovascular death comparing to placebo in patients with reduced ejection fraction further to standard of care. however, hypotensive patients who generally have higher risks comparing to normotensive patients, were under represented in the dapa-hf. the investigators aimed to evaluate clinical effects of dapagliflozin on hypotensive hfref patients receiving chronic sacubitril/valsartan (sal/val) treatment. this is an investigator-initiated, interventional, prospective. open-label study. the inclusion criteria were (1) chronic symptomatic hf with new york heart association (nyha) class ii-iv and lvef less than 40%, (2) treatment with stable and maximal tolerable dose of sac/val, beta-blocker with or without mineralocorticoid receptor antagonist (mra), (3) 6-minute walking-distance (6mwd)≥ 100meters and ≤425 meters at enrollment, (4) systolic blood pressure ≤100 mmhg at enrollment. the exclusion criteria were (1) type 1 diabetes mellitus, (2) patients previously treated with any sodium glucose co-transporter 2 inhibitor (sglt2i). after applying the inclusion and exclusion criteria, if the participants had type 2 diabetes mellitus, the participants will receive dapagliflozin 10mg daily directly. if the participants did not have history of diabetes mellitus, the participants will be allocated to either receiving dapagliflozin 10mg daily or receiving standard heart failure treatment without dapagliflozin. vital signs and laboratory tests were examined at baseline, 2-week, 4-week and 12-week. six-minute-walking-test, five-level euroqol five dimensions (eq-5d-5l) questionnaire and visual analogue scale (vas) were collected at baseline and at 12-week.

Eligibility criteria:
inclusion criteria: * chronic symptomatic hf with new york heart association (nyha) class ii-iv and left ventricular ejection fraction (lvef) less than 40% * treatment with stable and maximal tolerable dose of sac/val, beta-blocker with or without mineralocorticoid receptor antagonist * 6-minute walking-distance (6mwd)≥ 100meters and ≤425 meters at enrollment * systolic blood pressure ≤100 mmhg at enrollment exclusion criteria: * hemodialysis * severe co-morbidities with life expectancy less than 1 year * type 1 diabetes mellitus * ever treated with any type of sodium glucose cotransporter 2 inhibitor (sglt2i)

Keywords: heart failure dapagliflozin sacubitril/valsartan